Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis

NCT01988103 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01988103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01988103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
July 9, 2013
Completion date
December 15, 2015
Enrollment
254 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis, psoriasis arthropatica, psoriatic arthritis